Nordea Investment Management AB cut its stake in Eli Lilly and Company (NYSE:LLY) by 2.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 431,798 shares of the company’s stock after selling 10,686 shares during the period. Nordea Investment Management AB’s holdings in Eli Lilly and were worth $35,537,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of the business. Ronna Sue Cohen boosted its holdings in Eli Lilly and by 0.4% in the 2nd quarter. Ronna Sue Cohen now owns 2,466 shares of the company’s stock valued at $203,000 after purchasing an additional 9 shares during the period. Accredited Investors Inc. boosted its holdings in Eli Lilly and by 0.4% in the 2nd quarter. Accredited Investors Inc. now owns 3,259 shares of the company’s stock valued at $268,000 after purchasing an additional 14 shares during the period. Northwest Quadrant Wealth Management LLC boosted its holdings in Eli Lilly and by 0.5% in the 1st quarter. Northwest Quadrant Wealth Management LLC now owns 3,589 shares of the company’s stock valued at $290,000 after purchasing an additional 19 shares during the period. Oakworth Capital Inc. boosted its holdings in Eli Lilly and by 0.3% in the 2nd quarter. Oakworth Capital Inc. now owns 6,714 shares of the company’s stock valued at $552,000 after purchasing an additional 20 shares during the period. Finally, Sfmg LLC boosted its holdings in Eli Lilly and by 0.5% in the 2nd quarter. Sfmg LLC now owns 4,258 shares of the company’s stock valued at $350,000 after purchasing an additional 20 shares during the period. 75.48% of the stock is owned by hedge funds and other institutional investors.

In other Eli Lilly and news, SVP Alfonso G. Zulueta sold 2,003 shares of the firm’s stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the sale, the senior vice president now owns 43,580 shares in the company, valued at approximately $3,646,338.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $86.81, for a total transaction of $17,796,050.00. The disclosure for this sale can be found here. Insiders sold a total of 772,003 shares of company stock valued at $64,837,441 in the last 90 days. Corporate insiders own 0.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://www.dailypolitical.com/2017/11/15/eli-lilly-and-company-lly-position-lessened-by-nordea-investment-management-ab.html.

A number of analysts have weighed in on the stock. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, October 24th. Barclays PLC increased their price target on shares of Eli Lilly and from $90.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, October 13th. Berenberg Bank reissued a “buy” rating and issued a $98.00 price target on shares of Eli Lilly and in a report on Thursday, October 26th. Zacks Investment Research downgraded shares of Eli Lilly and from a “buy” rating to a “hold” rating in a report on Monday, October 30th. Finally, Cowen and Company reissued a “buy” rating and issued a $95.00 price target on shares of Eli Lilly and in a report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average target price of $89.76.

Shares of Eli Lilly and Company (LLY) opened at $82.49 on Wednesday. The stock has a market cap of $91,236.74, a PE ratio of 20.26, a P/E/G ratio of 1.83 and a beta of 0.34. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66. Eli Lilly and Company has a 1 year low of $64.18 and a 1 year high of $89.09.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. The business had revenue of $5.66 billion during the quarter, compared to analysts’ expectations of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm’s revenue for the quarter was up 9.0% on a year-over-year basis. During the same quarter last year, the company posted $0.88 EPS. analysts expect that Eli Lilly and Company will post 4.22 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be given a $0.52 dividend. This represents a $2.08 annualized dividend and a yield of 2.52%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s payout ratio is presently 98.58%.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.